|1.||Song, Xiaoling: 1 article (08/2013)|
|2.||Kim, Do-Young: 1 article (08/2013)|
|3.||Hazim, Antonious: 1 article (08/2013)|
|4.||Muir, Kyle: 1 article (08/2013)|
|5.||Peyressatre, Marion: 1 article (08/2013)|
|6.||He, Ying: 1 article (08/2013)|
|7.||Beretta, Laura: 1 article (08/2013)|
|8.||White, Emily: 1 article (01/2012)|
|9.||Sczaniecka, Anna K: 1 article (01/2012)|
|10.||Lampe, Johanna W: 1 article (01/2012)|
08/01/2013 - "This integrative proteomic and lipidomic study from mouse to human and from liver to blood identified the following disease signatures: (i) an HCC signature: upregulated hepatic scd1/scd2, fads2, and acsl5:acsl1 ratio, elevated vaccenic and erucic acids, and reduced margaric and linoleic acids in both liver and plasma; (ii) a NASH signature that correlates with tumor burden: upregulated hepatic elovl6, elevated oleic, adrenic, and osbond acids, and reduced cervonic acid in liver and plasma; and (iii) a NASH signature: reduced hepatic and circulating lignoceric and eicosapentaenoic acids. "
|2.||Adrenoleukodystrophy (Adrenoleukodystrophy, X-Linked)
09/09/1993 - "In this open trial we found no evidence of a clinically relevant benefit from dietary treatment with oleic and erucic acids ("Lorenzo's oil") in patients with adrenomyeloneuropathy."
09/09/1993 - "A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy."
07/01/2008 - "Considering the proposed preventive effect of nervonic acid on obesity- and diabetes-related coronary risk factors, the content of its precursors (oleic, 11-eicosenoic and 13-docosenoic acids) was measured in liver and plasma phospholipids and triglycerides, brain and spleen phospholipids, and adipose tissue lipids of fed or overnight fasted control and hereditarily diabetic Goto-Kakizaki female rats, as well as fed streptozotocin-induced diabetic female rats. "
|5.||Breast Neoplasms (Breast Cancer)